摘要
目的探讨地榆升白片治疗弥漫大B细胞淋巴瘤患者的可行性。方法将79例弥漫大B细胞淋巴瘤初治患者随机分为化疗组40例及联合组39例，化疗组应用标准CHOP方案行单纯化疗；联合组在化疗基础上口服地榆升白片0．4g，3次／d，第1～14天。两组均接受2周期治疗。流式细胞术检测两组治疗前后免疫指标（CD3^＋、CD4^＋、CD8^＋、CD4^＋／CD8^＋）和自然杀伤能力指标CD56^＋水平，另选择30例健康体检者为对照组。结果弥漫大B细胞淋巴瘤患者除CD；水平高于对照组，余均低于对照组；化疗组各项免疫指标治疗前后无明显变化；联合组与治疗前和化疗组治疗后比较，CD4^＋、CD56^＋、CD4^＋／CD8^＋值明显升高（P均〈0．05），CD8^＋明显降低（P〈0．05），CD3^＋无明显变化。结论T细胞亚群在弥漫大B细胞淋巴瘤患者中受到抑制，地榆升白片治疗能提高此类患者的细胞免疫功能，可作为弥漫大B细胞淋巴瘤的化疗辅助用药。
Objective To explore the feasibiltiy of diffuse large B-cell lymphoma （DLBCL） treated by Diyushengbai tablet. Methods Seventy-ninety patients with DLBCL were divided into chemotherapy group （n = 40） and combination group （n =39） ,the two groups were both treated with standard CHOP project, and the combination group was given Diyushengbai tablet 0.4 g orally,3 times/d × 1-14 d. Both groups took two cycles treatment. The immune indexes （CD3^＋, CD4^, CD8^＋ and CD4^＋/CD8^＋ ） and natural killing function indexes CD56^＋ were analyzed with flow cytometry before and after treatment respectively ,and 30 healthy subjects were taken as the control group. Results Lower levels were observed in DLBCL patients in all indexes except higher CD8^＋ compared with the control group; no significant pre- and post-treatment variation of immune function was found in the chemotherapy group. Raised CD4^＋, CD56^＋ and CD4^＋/CD8^＋ and lowered CD8^＋ were observed in combination group, compared with either its pre-treatment levels or post-treatment levels of chemotherapy group （ all P 〈 0.05）, without marked variation in CD3^＋. Conclusions T-lymphocyte subsets are suppressed in patients with DLBCL; Diyushengbai tablet can improve the cellular immune function of those patients and can be adopted as an adjuvant medication for DLBCL.
出处
《山东医药》
CAS
北大核心
2010年第11期28-30,共3页
Shandong Medical Journal
关键词
弥漫大B细胞淋巴瘤
地榆升白片
化学疗法
细胞免疫
diffuse large B-cell lymphoma
Diyushengbai tablet
chemotherapy
cellular immunity
